Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Capital Physio is one of the UK’s fastest growing providers of retail physiotherapy. Since inception in 2012, the group has opened 17 clinics as part of a highly scalable and growth driven business model.
days to go:
Expired
investment:
£6,210
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.
days to go:
Expired
investment:
£142,026
Sunswap is a solar and battery-powered transport refrigeration company that keeps food, medicine, and vaccines cold whilst on the road. The company argues that diesel-powered Transport Refrigeration Units (TRUs) are expensive to operate and highly polluting. It proclaims that replacing a diesel TRU with a Sunswap TRU could be the equivalent of removing 31 cars from the road. Sunswap asserts that the TRU market would have a market worth £13.4 billion by 2030. The company aims to be a contender in this segment and claims that electric TRU sales will follow the electric vehicle adoption curve with a 60% Year-on-Year growth. Sunswap has successfully tested its working prototype's capability to meet the temperature requirements of -22°C. It is collaborating with six major UK supermarkets on product development, with aims to secure sales with them in 2021. The company will use the investment to grow its team, build the next generation product, and secure sales by the end of 2021.
days to go:
Expired
investment:
£535,000
SHERPR is the ultimate door to door solution for transporting sports equipment, namely bikes, skis, snowboards and golf clubs. The company delivers premium packaging specifically designed to protect sports equipments in transit. The SHERPR business model taps into the growing leisure market with three core offerings: door to door transportation, bespoke logistic solutions for mass participation events, and a range of bike boxes. SHERPR has achieved impressive growth quarter on quarter and is currently looking to capitalize on the demands that it has created since its launch in 2017.
days to go:
Expired
investment:
£143,494
Six to Start are the co-creators of the popular fitness game 'Zombies, run!' and are now raising investment to grow this and to also build a new app called 'Virtual Races.' With over 3,000,000 downloads and peaks of 250k monthly active users, Zombie, Run! brings together audio storytelling and gameplay with real-world exercise. Virtual Races has already attracted over 15,000 entrants and generated over £600K+ in revenue.
days to go:
Expired
investment:
£249,970
